Simon Shenhav

Simon Shenhav has worked in the biotechnology industry since 1990. From 1990 to 2009, they held various positions, including Research Associate III at Alere Inc., Senior Scientist at Xen Biofluidx, and Director of Protein Engineering at Chemotrope LLC. In 2009, they joined GenWay Biotech as a Senior Scientist, where they developed chicken and sheep scFv against multiple antigens and designed antigens and antibodies using structural biology methods. In 2018, they moved to Janux Therapeutics as a Senior Principal Scientist and Scientist III, where they developed tumor actuated biologics to improve the safety and efficacy of these important classes of therapeutics.

Simon Shenhav received their B.Sc. in Biology from The Hebrew University of Jerusalem in 1984, and their M.Sc. in Microbiology and Immunology from the same university in 1986.